MiGenTra Aims to Ensure Equitable Access to Essential Medicines to Overcome Healthcare Inequality
MiGenTra strives to establish equitable access to high-quality biologics at affordable prices for Egypt, the Middle East, and Africa (MEA) while simultaneously strengthening regional and local manufacturing capacities. The company thus contributes to the Global Health Initiative and efforts by the World Health Organization (WHO) and the International Finance Corporation (IFC) to address urgent, unmet medical needs.
"Healthcare is not a privilege but a human right. We are committed to contributing to the transformational change across healthcare on the African continent.”
MiGenTra is a subsidiary of ProBioGen (Berlin, Germany) a renowned Contract Development and Manufacturing Organization (CDMO) and technology provider and Minapharm Pharmaceuticals (Cairo, Egypt), Africa’s primary biopharmaceutical company. Combining their scientific and manufacturing expertise MiGenTra has been established for product development and commercialization in the field of biosimilars, cell and gene therapies (CGT), and vaccines, capitalizing on the strong development capabilities and the excellent market position in the region. The company is based in Berlin, with management both in Berlin and Cairo.
- Founded 2021
- Based in Berlin, Germany
- Subsidiary of ProBioGen AG
(Germany) and Minapharm
Pharmaceuticals SE (Egypt)
- Biosimilars: proven track record in development and local manufacturing
- Cell and gene therapies (CGT): first-class knowledge and expertise in cell line and process development
- Vaccines: contract development and manufacturing of viral vectors at local facilities (Germany) and Minapharm Pharmaceuticals SE (Egypt)
Poised to Become a First Mover on the African Continent
The MEA region has long dealt with the repercussions of inadequate access to critical and lifesaving medicinal products. Fragile healthcare systems, expensive biologics, and limited regional manufacturing capacity has compounded the issue. This lack of access to affordable drugs and treatments could jeopardize the economic growth of these nations.
With patents on biologic drugs due to expire, now is the time to seize the opportunity to develop affordable alternatives. However, time is of the essence. Data shows that only the first four products to market will garner enough of the market share to offset R&D expenses and secure future development. MiGenTra, guided by the WHO and IFC global health initiative on affordable medicine and treatment access, is poised to transform healthcare in the MEA region.
MiGenTra’s disruptive go-to-market business model and strategic partnerships will position MEA as a new global hub for healthcare product manufacturing.
Thanks to Minapharm’s continued regional success over global players and its solid track record in biological drug development and ProBioGen’s cutting-edge technologies and unparalleled knowledge in the development and manufacture of active ingredients and vaccines, MiGenTra is poised to succeed at closing the gap to equitable medical access.
- Evaluate large untapped market opportunities for healthcare products already in development
- Build collaborations with biopharmaceutical partners for commercialization and branding
- Select new molecules as well as early in-house development of wave 3 molecules
Dedicated to overcoming disparity on the African continent and beyond by bringing healthcare transforming products and services to market MiGenTra is driven by a diversified and highly experienced management team with in-depth knowledge of the region.
Dr. Wafik Bardissi has been working in the pharmaceutical and biopharmaceutical industry for more than 25 years and has held various executive positions. He is the Chairman and CEO of Minapharm Pharmaceuticals, a regional pharma and biopharma leader in Egypt and the Middle East. In 2001, Wafik founded the first state-of-the-art biotech manufacturing operation in Africa and the MENA region. In 2010, he signed the deal to acquire ProBioGen AG, a global German biotech cellular engineering and CDMO specialist. Wafik is also the CEO of Amplifon Middle East s.a.e., a subsidiary of Amplifon spa, a multi-national world leader in hearing technology services. Wafik earned his Bachelor’s degree in Medicine and Surgery (MB, BCh) from Cairo University. He pursued his research interests in Business Information Technology (MSc.) at the School of Computing Sciences in Middlesex, London, and Operational Research (MSc.) and Complex Decision Sciences and Artificial Intelligence (PhD) at the University of Strathclyde in Glasgow. In 2010, Wafik was honored with the Knighthood (cavalry) of the Pontifical Equestrian Order of St. Gregory the Great by his Holiness Pope Benedict XVI in recognition of his pioneering social work.
Dr. Lutz Hilbrich, Senator at Senate of Economy Europe, holds a Medical Degree from the Julius-Maximilians-University, Würzburg, Germany and an MBA from Stern School of Business at NYU, USA. Before joining ProBioGen, he was the Head of the Biosimilars Platform China for Sanofi and second-in-command for the Biosimilars Business Unit at Boehriger Ingelheim GmbH, Germany. He is experienced in CMC, pre-clinical, and clinical development but also in business development and market access strategies. Besides serving on a couple of organizational committees for international conferences on biologics and biosimilars, he is on the Biosimilar Advisory Board of the American Conference Institute (ACI). Since June 2020, he has been CEO of ProBioGen. Under his leadership, the idea of spinning out a product development company materialized with the incorporation of MiGenTra GmbH in April 2021.
Dr. Shaheer Bardissi is an executive board member at Minapharm pharmaceuticals and advisory board member at MiGenTra GmbH. Shaheer has been assigned the responsibility of aiding the steering of the growth strategy of the Minapharm group in the field of immuno-oncology, vaccines for infectious diseases, and gene and cell-based therapies in collaboration with its global subsidiaries. Shaheer previously worked at BioNTech SE and contributed to the successful development of immunotherapeutic technologies in the field of cell and gene therapy. Shaheer obtained his PhD from Johannes Gutenberg University, Mainz, Germany, with a focus on gene-based immunotherapy. Prior to that, he completed his Masters of Science in Molecular Medicine at University College London, Bachelors of Science in Biomedical Sciences from King's college London, and also holds a Masters of Science in quantitative management sciences and healthcare data analytics from Duke University, North Carolina, USA.
Be Part of the Transformational Change Across Healthcare
Are you interested in being part of a team committed to sustainable change in global healthcare and providing affordable and critical medical treatments? Then learn more about our career opportunities and find out how you can make a lasting impact.